Immunopathogenesis of Leishmania infections;Leishmania enfeksiyonlarιnιn immünopatogenezi

Mikrobiyoloji Bulteni

Volumn 39, Issue 3, 2005, Pages 363-381

  Yurdakul, Pinar ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cutaneous leishmaniasis; Immunopathogenesis; Leishmania; Visceral leishmaniasis

Indexed keywords

ANIMAL; CELLULAR IMMUNITY; DISEASE CARRIER; DISEASE MODEL; HOST PARASITE INTERACTION; HUMAN; IMMUNOLOGY; LEISHMANIA; LEISHMANIASIS; PARASITOLOGY; PATHOGENICITY; PSYCHODIDAE; REVIEW; VIRULENCE;

ANIMALS; DISEASE MODELS, ANIMAL; HOST-PARASITE RELATIONS; HUMANS; IMMUNITY, CELLULAR; INSECT VECTORS; LEISHMANIA; LEISHMANIASIS; PSYCHODIDAE; VIRULENCE;

EID: 33846456287     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Pearson RD, Sousa ADQ, Jeronimo SM: Leishmania Species: Visceral (Kala-Azar), Cutaneous and Mucosal Leishmaniasis, p: 2831-2841. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6th ed, 2005. Churchill Livingstone, Philadelphia.
2. Desjeux P: Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27: 305-318. 3 Leishmaniasis: Strategic Direction for Research, Feb 2002. TDR, www.who.int/dr/diseases/ leish/direction.htm
3. TDR Publications: Scientific Working Group on Leishmaniasis, Meeting Report. Feb 2004. www.who.int/dr/publications/publications /swg_leish.htm
4. Uz O, Balcioglu IC, Taylan Ozkan A, Ozensoy S, Ozbel Y: Leishmaniasis in Turkey. Acta Trop 2002, 84: 43-48.
5. Alexander J, Satoskar AR, Russhell DG: Leishmania species: Models of intracellular parasitism. J Cell Sci 1999, 18: 2993-3002.
6. Awasthi A, Mathur RK, Saha B: Immune response to Leishmania infection. Indian J Med Res 2004, 119: 238-258.
7. de Almeida MC, Vilhena V, Barral A, Barral-Netto M: Leishmanial infection: Analysis of its first steps. Mem Inst Oswaldo Cruz 2003, 98: 861-870.
8. Chang KP, McGwire BS: Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol Dis 2002, 1: 1.
9. Sacks D, Sher A: Evasion of innate immunity by parasitic protozoa. Nat Immunol 2002, 3: 1041-1047.
10. Rivas L, Moreno J, Canavate C, Alvar J: Virulence and disease in leishmaniasis: What is relevant for the patient? Trends Parasitol 2004, 20: 297-301.
11. Spath GF, Garraway LA, Turco SJ, Beverley SM: The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci USA 2003, 100: 9536-9541.
12. Bogdan C, Rollinghoff M: The immune response to Leishmania: Mechanisms of parasite control and evasion. Int J Parasitol 1998, 28: 121-134.
13. Bogdan C, Gessner A, Solbach W, Rollinghoff M: Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 1996, 8: 517-525.
14. Requena JM, Alonso C, Soto M: Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today 2000, 16: 246-250.
15. Sacks D, Noben-Trauth N: The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002, 2: 845-858.
16. von Stebut E, Udey MC: Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 2004, 6: 1102-1109. 18 Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3: 133-146.
17. Korbel DS, Finney OC, Riley EM: Natural killer cells and innate immunity to protozoan pathogens. Int J Parasitol 2004, 34: 1517-1528.
18. Brandonisio O, Spinelli R, Pepe M: Dendritic cells in Leishmania infection. Microbes Infect 2004, 6: 1402-1409.
19. Sher A, Pearce E, Kaye PM: Shaping the immune response to parasites: Role of dendritic cells. Curr Opin Immunol 2003, 15: 421-429.
20. Moll H: Dendritic cells and host resistance to infection. Cell Microbiol 2003, 5: 493-500.
21. Engwerda CR, Ato M, Kaye PM: Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004, 20: 524-530.
22. Kaye PM, Svennson M, Ato M, et al: The immunopathology of experimental visceral leishmaniasis. Immunol Rev 2004, 201: 239-253.
23. Wilson ME, Jeronimo SM, Pearson RD: Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005, 38: 147-160.
24. Gorak PM, Engwerda CR, Kaye PM: Dendritic cells, but not macrophages, produce IL-12 immediately following L.donovani infection. Eur J Immunol 1998, 28: 687-695.
25. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM: Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 1998, 28: 669-680.
26. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP: IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001, 31: 2848-2856.
27. Svennson M, Maroof A, Ato M, Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 2004, 21: 805-816.
28. Engwerda CR, Ato M, Stager S, Alexander CE, Stanley AC, Kaye PM: Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol 2004, 165: 2123-2133.
29. Engwerda CR, Ato M, Cotterell SE, et al: The role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol 2002, 161: 429-437. 32 Ato M, Nakano H, Kakiuchi T, Kaye PM: Localization of marginal zone macrophages is regulated by C-C chemokine ligands 21/19. J Immunol 2004, 173: 4815-4820.
30. Cotterell SE, Engwerda CR, Kaye PM: Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani. Infect Immun 2000, 68: 1840-1848.
31. Davies CR, Kaye P, Croft SL, Sundar S: Leishmaniasis: New approaches to disease control. BMJ 2003, 326: 377-382.
32. Melby PC: Recent developments in leishmaniasis. Curr Opin Infect Dis 2002, 15: 485-490.
33. Sinha PK, Pandey K, Bhattacharya SK: Diagnosis and management of Leishmania/HIV co-infection. Indian J Med Res 2005, 121: 407-414.
34. Vanloubbeeck Y, Jones DE: The immunology of Leishmania infection and the implications for vaccine development. Ann N Y Acad Sci 2004, 1026: 267-272.
35. Kubar J, Fragaki K: Recombinant DNA-derived Leishmania proteins: From the laboratory to the field. Lancet 2005, 5: 107-114.
36. Zubairi S, Sanos SL, Hill S, Kaye PM: Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004, 34: 1433-1440.